ACP-211 vs Blixeprodil
Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.
Major Depressive Disorder
Shared mechanism: NMDA receptor · full Major Depressive Disorder pipeline
ACP-211
Developed by Acadia Pharmaceuticals
No graded featured trial for this indication yet; the grade above reflects that absence, not a judgment.
Next expected readout: August 2027 · NCT07284667 (registry estimate)
No aligned efficacy figure on record for this race.
Blixeprodil
Developed by Gilgamesh Pharma
NCT06309277 · Phase 2 · completed
This two-part, randomized, quadruple-blind, placebo-controlled Phase 2a study gave single and multiple oral doses of GM-1020 (blixeprodil) or placebo to 46 patients with major depressive disorder. The only registered primary outcome is the incidence of treatment-emergent adverse events, which has no formal efficacy test, so there is no met or missed result. Antidepressant response was a preliminary, non-primary aim. Source: CT.gov posted results. Its registered primary outcome on ClinicalTrials.gov is "Incidence of Treatment Emergent Adverse Events". Its registered primary outcomes are safety, tolerability or dose-finding measures only, so the evidence grade is capped at weak.
Reported efficacy
Incidence of Treatment Emergent Adverse Events (Baseline, Day 29): Primary outcome, incidence of treatment-emergent adverse events to Day 29 (no formal efficacy test): Part A, 23 participants on placebo and 43 on GM-1020 140 mg with at least one TEAE (CT.gov posted results). (not_applicable)
Result source: NCT06309277
Results for Major Depressive Disorder
Values come from each drug's own ClinicalTrials.gov study. They are from separate trials and patient populations, not a head-to-head comparison. Each result identifies its source trial, phase, arm and timepoint; limitations that apply to a whole cell are marked with a letter and listed once beneath the table. The comparison is deepest for later-stage drugs (phase 3 or approved), which usually have posted results to draw on; early-stage drugs often have none yet.
| Key endpoint | ACP-211 | Blixeprodil |
|---|---|---|
| MADRS, change (acute) | —Not reported | -10.5 vs -5.4−5.1 vs placeboNCT063092771 other result
|
| CGI-S, change (acute) | —Not reported | —Not reported |
| MADRS response | —Not reported | —Not reported |
| MADRS remission | —Not reported | —Not reported |
| Relapse (% of patients) | —Not reported | —Not reported |
MADRS, change (acute)
- ACP-211
- —Not reported
- Blixeprodil
- -10.5 vs -5.4−5.1 vs placeboNCT06309277
1 other result
- -12.1 vs -5.8 NCT06309277
CGI-S, change (acute)
- ACP-211
- —Not reported
- Blixeprodil
- —Not reported
MADRS response
- ACP-211
- —Not reported
- Blixeprodil
- —Not reported
MADRS remission
- ACP-211
- —Not reported
- Blixeprodil
- —Not reported
Relapse (% of patients)
- ACP-211
- —Not reported
- Blixeprodil
- —Not reported
- Each cell is from that drug's own trial. Trials differ in population, design and timepoint; this is not a head-to-head comparison.
- An empty cell names why: Not posted (a completed Phase 3 here has no posted results yet), Trial running, Pending review (we hold the result and are checking it) or Not reported.
ACP-211: no structured comparison results are available for Major Depressive Disorder.
Only safety results can currently be compared in this indication. Reviewed efficacy summaries, where available, are listed separately.
safety
Coverage. ACP-211: 0 of 4 rows · Blixeprodil: 2 of 4 rows. A dash means no reviewed, structured value is available for that endpoint in this indication.
| Reported metric | Blixeprodil |
|---|---|
| Dropout rate | —210 mg NCT06309277 · Phase 2 · monotherapy · Major Depressive Disorder · phase 2 show 2 more results—140 mg NCT06309277 · Phase 2 · monotherapy · Major Depressive Disorder · phase 2 —140 mg NCT06309277 · Phase 2 · monotherapy · Major Depressive Disorder · phase 2 |
| Discontinued due to AEs | —210 mg NCT06309277 · Phase 2 · monotherapy · Major Depressive Disorder · phase 2 show 2 more results—140 mg NCT06309277 · Phase 2 · monotherapy · Major Depressive Disorder · phase 2 —140 mg NCT06309277 · Phase 2 · monotherapy · Major Depressive Disorder · phase 2 |
| Serious AEs | 0%210 mg NCT06309277 · Phase 2 · monotherapy · Major Depressive Disorder · phase 2 show 2 more results0%140 mg NCT06309277 · Phase 2 · monotherapy · Major Depressive Disorder · phase 2 0%140 mg NCT06309277 · Phase 2 · monotherapy · Major Depressive Disorder · phase 2 |
| Most frequent reported AEs | 210 mg time perception altered 63.2% (placebo 0%) euphoric mood 57.9% (placebo 0%) hallucination, visual 57.9% (placebo 0%) NCT06309277 · Phase 2 · monotherapy · Major Depressive Disorder · phase 2 show 2 more results140 mg dizziness 46.5% (placebo 4.5%) euphoric mood 44.2% (placebo 0%) headache 37.2% (placebo 18.2%) NCT06309277 · Phase 2 · monotherapy · Major Depressive Disorder · phase 2 140 mg euphoric mood 61.1% (placebo 0%) dizziness 50% (placebo 4.5%) headache 50% (placebo 18.2%) NCT06309277 · Phase 2 · monotherapy · Major Depressive Disorder · phase 2 |
Reported by one asset only
Endpoints only one of the selected assets measured, so there is nothing to compare them against.
Blixeprodil
show 1 more result
The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: ACP-211's landscape · Blixeprodil's landscape